(Q44738462)

5 December 2017

Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia (English)

1 reference

5 December 2017

1 reference

K Lindahl

1

1 reference

5 December 2017

R Schvarcz

series ordinal

2

1 reference

5 December 2017

A Bruchfeld

series ordinal

3

1 reference

5 December 2017

L Ståhle

series ordinal

4

1 reference

5 December 2017

1 January 2004

1 reference

Journal of Viral Hepatitis

5 December 2017

1 reference

5 December 2017

11

1 reference

5 December 2017

84-87

1 reference

5 December 2017

1

1 reference

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

5 December 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00475.X

Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00475.X

Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00475.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00475.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00475.X

Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00475.X

Determination of ribavirin in serum using highly selective solid-phase extraction and high-performance liquid chromatography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00475.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00475.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2003.00475.X

10.1046/J.1365-2893.2003.00475.X

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference